Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Int J Radiat Oncol Biol Phys Retrieve available abstracts of 220 articles: HTML format

Single Articles

April 2023
1. PISANSKY TM
   Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy: Brachytherapy as Dose Escalation for Localized Prostate Cancer.
   Int J Radiat Oncol Biol Phys. 2023;115:1071-1073.
   PubMed    
   
   
   March 2023
2. HOULIHAN OA, Redmond K, Fairmichael C, Lyons CA, et al
   A Randomised Feasibility Trial of Stereotactic Prostate Radiotherapy with or without Elective Nodal Irradiation in High-Risk Localised Prostate Cancer (SPORT Trial).
   Int J Radiat Oncol Biol Phys. 2023 Mar 7:S0360-3016(23)00217.
   PubMed     Abstract available
   
   
   February 2023
3. SMITH CP, Xiang M, Armstrong WR, Nickols NG, et al
   Patterns of Failure in Men with Radiorecurrent Prostate Cancer: A Post-Hoc Analysis of Three Prospective Ga-68-PSMA PET/CT Imaging Trials.
   Int J Radiat Oncol Biol Phys. 2023 Feb 28:S0360-3016(23)00181.
   PubMed     Abstract available
   
   
   
4. PARR H, Porta N, Tree AC, Dearnaley D, et al
   A Personalised Clinical Dynamic Prediction Model to Characterise Prognosis for Patients with Localised Prostate Cancer: analysis of the CHHiP Phase III Trial.
   Int J Radiat Oncol Biol Phys. 2023 Feb 21:S0360-3016(23)00167.
   PubMed     Abstract available
   
   
   
5. BRAND DH, Bruningk SC, Wilkins A, Naismith O, et al
   The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha/Beta (alpha/beta) Ratios in the CHHiP Trial.
   Int J Radiat Oncol Biol Phys. 2023;115:327-336.
   PubMed     Abstract available
   
   
   
6. CHEN J, Zhao N, Copello V, Ru Y, et al
   Accurate and Early Metastases Diagnosis in Live Animals With Multimodal X-ray and Optical Imaging.
   Int J Radiat Oncol Biol Phys. 2023;115:511-517.
   PubMed     Abstract available
   
   
   
7. BAI J, Pugh SL, Eldridge R, Yeager KA, et al
   Neighborhood Deprivation and Rurality Associated with Patient-Reported Outcomes and Survival in Men with Prostate Cancer in NRG RTOG 0415.
   Int J Radiat Oncol Biol Phys. 2023 Feb 1:S0360-3016(23)00082.
   PubMed     Abstract available
   
   
   January 2023
8. SUTERA P, Deek MP, Van der Eecken K, Shetty AC, et al
   WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer.
   Int J Radiat Oncol Biol Phys. 2023 Jan 25:S0360-3016(22)03628.
   PubMed     Abstract available
   
   
   
9. PETIT C, Delouya G, Taussky D, Barkati M, et al
   PSMA-PET/CT guided intensification of radiotherapy for prostate cancer (PSMAgRT): Findings of detection rate, impact on cancer management, and early toxicity from a phase 2 randomised controlled trial.
   Int J Radiat Oncol Biol Phys. 2023 Jan 10:S0360-3016(23)00006.
   PubMed     Abstract available
   
   
   
10. 
    Erratum to: Jones, CU; Pugh, SL; Sandler, HM; Chetner, MP; Amin, MB; Bruner, DW; Zietman, AL; Den, RB; Leibenhaut, MH; Longo, JM; Bahary, JP; Rosenthal, SA; Souhami, L; Michalski, JM; Hartford, AC; Amin, PP; Roach, M 3rd; Yee, D; Efstathiou, JA; Rodge
    Int J Radiat Oncol Biol Phys. 2023;115:265.
    PubMed    
    
    
    
11. HALL WA, Lawton CAF
    Confirming and Refining Our Existing Postoperative Treatment Strategies Through the Use of Novel Prostate-Specific Positron Emission Tomography (PET) Imaging.
    Int J Radiat Oncol Biol Phys. 2023;115:118-119.
    PubMed    
    
    
    
12. HORSLEY PJ, Koo CM, Eade T, Hsiao E, et al
    Mapping of Local Recurrences After Radical Prostatectomy Using 68-Gallium-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: Implications for Postprostatectomy Radiation Therapy Clinical Target Volumes.
    Int J Radiat Oncol Biol Phys. 2023;115:106-117.
    PubMed     Abstract available
    
    
    December 2022
13. NGUYEN PL, Huang HR, Spratt DE, Davicioni E, et al
    Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: Meta-analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials.
    Int J Radiat Oncol Biol Phys. 2022 Dec 31:S0360-3016(22)03688.
    PubMed     Abstract available
    
    
    
14. SPOHN SKB, Draulans C, Kishan AU, Spratt D, et al
    Genomic classifiers in personalized prostate cancer radiotherapy approaches - a systematic review and future perspectives based on international consensus.
    Int J Radiat Oncol Biol Phys. 2022 Dec 31:S0360-3016(22)03691.
    PubMed     Abstract available
    
    
    
15. LUKKA HR, Deshmukh S, Bruner DW, Bahary JP, et al
    Five-year patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer.
    Int J Radiat Oncol Biol Phys. 2022 Dec 30:S0360-3016(22)03671.
    PubMed     Abstract available
    
    
    
16. ZHANG E, Ruth KJ, Buyyounouski MK, Price RA Jr, et al
    Long Term Results of a Phase III Randomized Prospective Trial of Erectile Tissue Sparing IMRT for Men with Clinically Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Dec 22:S0360-3016(22)03627.
    PubMed     Abstract available
    
    
    
17. LIU W, Bauman G
    PSMA PET- and mpMRI-directed Prostate Cancer Salvage.
    Int J Radiat Oncol Biol Phys. 2022;114:1053-1054.
    PubMed    
    
    
    
18. YANG DD, Brennan VS, Huynh E, Williams CL, et al
    Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Abdominopelvic Oligometastases.
    Int J Radiat Oncol Biol Phys. 2022;114:941-949.
    PubMed     Abstract available
    
    
    November 2022
19. CHOO R, Hillman DW, Mitchell C, Daniels T, et al
    Late toxicity of moderately hypofractionated intensity-modulated proton therapy treating the prostate and pelvic lymph nodes for high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2022 Nov 22:S0360-3016(22)03555.
    PubMed     Abstract available
    
    
    
20. CHRIST SM, Pohl K, Muehlematter UJ, Heesen P, et al
    Imaging-Based Prevalence of Oligometastatic Disease: A Single-Center Cross-Sectional Study.
    Int J Radiat Oncol Biol Phys. 2022;114:596-602.
    PubMed     Abstract available
    
    
    
21. KERANS SJ, Samanta S, Vyfhuis MAL, Guerrero M, et al
    Racial Analysis of Clinical & Biochemical Outcomes in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2022 Nov 3. pii: S0360-3016(22)03474.
    PubMed     Abstract available
    
    
    
22. BARNETT GC, Kerns SL, Dorling L, Fachal L, et al
    No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity.
    Int J Radiat Oncol Biol Phys. 2022;114:494-501.
    PubMed     Abstract available
    
    
    September 2022
23. PATEL SA, Ma TM, Wong JK, Stish BJ, et al
    External Beam Radiotherapy With or Without Brachytherapy Boost in Men with Very High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.
    Int J Radiat Oncol Biol Phys. 2022 Sep 27. pii: S0360-3016(22)03399.
    PubMed     Abstract available
    
    
    
24. TREE AC, Satchwell L, Alexander E, Blasiak-Wal I, et al
    Standard and hypofractionated dose escalation to intraprostatic tumour nodules in localised prostate cancer: 5 year efficacy and toxicity in the DELINEATE trial.
    Int J Radiat Oncol Biol Phys. 2022 Sep 20. pii: S0360-3016(22)03349.
    PubMed     Abstract available
    
    
    August 2022
25. GLICKSMAN RM, Ramotar M, Metser U, Chung PW, et al
    Extended Results and Independent Validation of a Phase 2 Trial of Metastasis Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Aug 25. pii: S0360-3016(22)00644.
    PubMed     Abstract available
    
    
    
26. MA TM, Ballas LK, Wilhalme H, Sachdeva A, et al
    Quality-of-Life Outcomes and Toxicity Profile Among Patients with Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multi-Center Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2022 Aug 22. pii: S0360-3016(22)03160.
    PubMed     Abstract available
    
    
    July 2022
27. SHEN X, Spratt DE, Dusetzina SB, Chen RC, et al
    Variations in Medical Necessity Determinations Across Commercial Insurance Carriers for Prostate Cancer Procedures.
    Int J Radiat Oncol Biol Phys. 2022 Jul 30. pii: S0360-3016(22)02597.
    PubMed     Abstract available
    
    
    
28. USMANI N, Ghosh S, Sanghera KP, Ong AD, et al
    Metformin for Prevention of Anthropometric & Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2022 Jul 27. pii: S0360-3016(22)00747.
    PubMed     Abstract available
    
    
    
29. CHINNIAH S, Stish B, Costello BA, Pagliaro L, et al
    Radiotherapy in Oligometastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jul 22. pii: S0360-3016(22)00732.
    PubMed     Abstract available
    
    
    
30. HAMMER L, Jiang R, Hearn J, Lashbrook J, et al
    A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jul 22. pii: S0360-3016(22)00736.
    PubMed     Abstract available
    
    
    
31. CHOPADE P, Maitre P, David S, Panigrahi G, et al
    Common iliac node positive prostate cancer treated with curative radiotherapy: N1 or M1a?
    Int J Radiat Oncol Biol Phys. 2022 Jul 20. pii: S0360-3016(22)00731.
    PubMed     Abstract available
    
    
    
32. JANES JL, Boyer MJ, Bennett J, Thomas VM, et al
    The 17-Gene Genomic Prostate Score(R) Test is Prognostic for Outcomes after Primary External Beam Radiation Therapy in Men with Clinically Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jul 17. pii: S0360-3016(22)00718.
    PubMed     Abstract available
    
    
    
33. BRAND DH, Tree AC
    Fractionation Choice for Elective Lymph Node Radiation Therapy in Prostate Cancer: Slightly More to CHIRP About.
    Int J Radiat Oncol Biol Phys. 2022 Jul 14. pii: S0360-3016(22)00485.
    PubMed    
    
    
    
34. HAO C, Ladbury C, Lyou Y, Manoukian S, et al
    Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and External Beam Radiation.
    Int J Radiat Oncol Biol Phys. 2022 Jul 5. pii: S0360-3016(22)00659.
    PubMed     Abstract available
    
    
    
35. CHARGARI C, Haie-Meder C, Espenel S, Garcia MA, et al
    Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments.
    Int J Radiat Oncol Biol Phys. 2022;113:602-613.
    PubMed     Abstract available
    
    
    June 2022
36. MURTHY V, Adsul K, Maitre P, Singhla A, et al
    Acute and late toxicity of prostate-only or pelvic SBRT in prostate cancer: A Comparative Study.
    Int J Radiat Oncol Biol Phys. 2022 Jun 17. pii: S0360-3016(22)00607.
    PubMed     Abstract available
    
    
    
37. HALL WA, Karrison TG, Rosenthal SA, Amin MB, et al
    The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High Risk Prostate Cancer: A Validation Study from NRG/RTOG 0521.
    Int J Radiat Oncol Biol Phys. 2022 Jun 5. pii: S0360-3016(22)00555.
    PubMed     Abstract available
    
    
    
38. RICH BJ, Montoya C, Jin WH, Spieler BO, et al
    Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jun 4. pii: S0360-3016(22)00545.
    PubMed     Abstract available
    
    
    
39. LUCIEN F, Kim Y, Qian J, Orme JJ, et al
    Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity.
    Int J Radiat Oncol Biol Phys. 2022 Jun 4. pii: S0360-3016(22)00544.
    PubMed     Abstract available
    
    
    
40. ZAMBOGLOU C, Strouthos I, Sahlmann J, Farolfi A, et al
    Metastasis-free survival and patterns of distant metastatic disease after PSMA-PET-guided salvage radiotherapy in recurrent or persistent prostate cancer after prostatectomy.
    Int J Radiat Oncol Biol Phys. 2022 Jun 2. pii: S0360-3016(22)00409.
    PubMed     Abstract available
    
    
    
41. JIA AY, Spratt DE
    Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative.
    Int J Radiat Oncol Biol Phys. 2022;113:316-319.
    PubMed    
    
    
    
42. ZELEFSKY MJ
    Are We Ready for Focal Dose Radio-Ablation in the Treatment of Localized Prostate Cancer?
    Int J Radiat Oncol Biol Phys. 2022;113:302-304.
    PubMed    
    
    
    
43. MOHAMAD O, Feng F
    The Time to Evaluate the Impact of PET PSMAs on Management of Prostate Cancer Is Now.
    Int J Radiat Oncol Biol Phys. 2022;113:254-255.
    PubMed    
    
    
    
44. BERGHEN C, De Meerleer G
    Postoperative Radiation Therapy in Prostate Cancer: Timing, Duration of Hormonal Treatment and the Use of PSMA PET-CT.
    Int J Radiat Oncol Biol Phys. 2022;113:252-253.
    PubMed    
    
    
    
45. STENMAN J, Wickart-Johansson G, Sundquist F, Nilsson J, et al
    Five-Year Follow-up After Multimodal Treatment Incorporating HDR Brachytherapy for Bladder Prostate Rhabdomyosarcoma in Children.
    Int J Radiat Oncol Biol Phys. 2022;113:355-359.
    PubMed    
    
    
    
46. TREE A, Griffin C, Syndikus I, Birtle A, et al
    Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial.
    Int J Radiat Oncol Biol Phys. 2022;113:305-315.
    PubMed     Abstract available
    
    
    May 2022
47. YANG F, Ghosh S, Yee D, Patel S, et al
    Patient-Reported Outcomes in a Prostate Cancer Hypofractionation Trial.
    Int J Radiat Oncol Biol Phys. 2022 May 7. pii: S0360-3016(22)00406.
    PubMed     Abstract available
    
    
    
48. ZILLI T, Achard V, Guevelou JL
    Intraprostatic Urethra: The New Kid on the Block for Prostate Cancer Radiation Therapy?
    Int J Radiat Oncol Biol Phys. 2022;113:92-95.
    PubMed    
    
    
    
49. DESS RT
    Personalized Medicine in Localized Prostate Cancer: Are We There Yet?
    Int J Radiat Oncol Biol Phys. 2022;113:77-79.
    PubMed    
    
    
    
50. 
    Erratum to: Sanders JW, Venkatesan AM, Levitt CA, et al. Fully balanced SSFP without an endorectal coil for post-implant QA of MRI-assisted radiosurgery (MARS) of prostate cancer: a prospective study. Int J Radiat Oncol Biol Phys 2021;109(2):614-625.
    Int J Radiat Oncol Biol Phys. 2022;113:238.
    PubMed    
    
    
    
51. BECK M, Sassowsky M, Schar S, Mathier E, et al
    Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial.
    Int J Radiat Oncol Biol Phys. 2022;113:80-91.
    PubMed     Abstract available
    
    
    
52. TWARD J, Lenz L, Flake DD II,, Rajamani S, et al
    The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.
    Int J Radiat Oncol Biol Phys. 2022;113:66-76.
    PubMed     Abstract available
    
    
    April 2022
53. ZAMBOGLOU DC, Spohn DSKB, Ruf PJ, Benndorf DM, et al
    PSMA-PET- and MRI-based focal dose escalated radiotherapy of primary prostate cancer: planned safety analysis of a non-randomized 2-armed phase II trial (ARO2020-01).
    Int J Radiat Oncol Biol Phys. 2022 Apr 22. pii: S0360-3016(22)00333.
    PubMed     Abstract available
    
    
    
54. VIANI GA, Gouveia AG, Moraes FY, Cury FL, et al
    "Meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer" (MENHYP-ENI).
    Int J Radiat Oncol Biol Phys. 2022 Apr 15. pii: S0360-3016(22)00321.
    PubMed     Abstract available
    
    
    
55. KWAN W, Bahl G, Kim D, Ye A, et al
    Acute Toxicity of Ultrahypofractionation Compared to Moderate Hypofractionation in Prostate Cancer Treatment - a Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2022 Apr 10. pii: S0360-3016(22)00319.
    PubMed     Abstract available
    
    
    
56. DHERE VR, Schuster DM, Goyal S, Schreibmann E, et al
    Randomized Trial of Conventional- vs Conventional plus Fluciclovine (18F) PET/CT-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer: Volumetric and Patient-Reported Toxicity Analyses.
    Int J Radiat Oncol Biol Phys. 2022 Apr 10. pii: S0360-3016(22)00318.
    PubMed     Abstract available
    
    
    
57. THIRUTHANEESWARAN N, Turner SL
    Prostate Cancer Patients to Reap the Benefits of "Seeds" Planted by NRG Oncology/RTOG 0526.
    Int J Radiat Oncol Biol Phys. 2022;112:1123-1125.
    PubMed    
    
    
    
58. CROOK J, Rodgers JP, Pisansky TM, Trabulsi EJ, et al
    Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).
    Int J Radiat Oncol Biol Phys. 2022;112:1115-1122.
    PubMed     Abstract available
    
    
    March 2022
59. ZUMSTEG ZS
    Personalization of Treatment Intensity for Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022;112:744-746.
    PubMed    
    
    
    February 2022
60. LAMPROU I, Kakouratos C, Tsolou A, Pavlidis P, et al
    Lipophagy-related protein perilipin-3 (PLIN3) and resistance of prostate cancer to radiotherapy.
    Int J Radiat Oncol Biol Phys. 2022 Feb 1. pii: S0360-3016(22)00079.
    PubMed     Abstract available
    
    
    
61. TREE A
    Androgen Deprivation Therapy, Perseverance, and Greek Mythology.
    Int J Radiat Oncol Biol Phys. 2022;112:304-305.
    PubMed    
    
    
    January 2022
62. RAMAN S, Keyes M, Oh J, Rousseau E, et al
    Patterns of prostate cancer recurrence after brachytherapy determined by PSMA PET/CT imaging.
    Int J Radiat Oncol Biol Phys. 2022 Jan 2. pii: S0360-3016(21)03437.
    PubMed     Abstract available
    
    
    
63. GLICKSMAN RM, Berlin A
    FACE Value of Patient-Reported Outcomes in Dose-Escalated Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022;112:93-95.
    PubMed    
    
    
    
64. HALL WA, Deshmukh S, Bruner DW, Michalski JM, et al
    Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126.
    Int J Radiat Oncol Biol Phys. 2022;112:83-92.
    PubMed     Abstract available
    
    
    
65. LEEMAN JE, Chen YH, Catalano P, Bredfeldt J, et al
    Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials.
    Int J Radiat Oncol Biol Phys. 2022;112:75-82.
    PubMed     Abstract available
    
    
    December 2021
66. ROY S, Zaorsky NG, Bagshaw HP, Berlin A, et al
    An Expert Review on the Combination of Relugolix with Definitive Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Dec 16. pii: S0360-3016(21)03240.
    PubMed     Abstract available
    
    
    
67. WILLETT GCECG, Chang DT, Czito BG, Liauw SL, et al
    Reflections on Anthony Zietman From Gastrointestinal Cancer and Physics Editors.
    Int J Radiat Oncol Biol Phys. 2021;111:1114-1117.
    PubMed    
    
    
    
68. HARMON G, Chan D, Lee B, Miller C, et al
    Validating Modern NRG Oncology Pelvic Nodal and Groupe Francophone de Radiotherapie Urologique Prostate Bed Contouring Guidelines for Post-Prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial.
    Int J Radiat Oncol Biol Phys. 2021;111:1195-1203.
    PubMed     Abstract available
    
    
    November 2021
69. ZAORSKY NG, Spratt DE
    Elective Nodal Radiotherapy for Prostate Cancer: For None, Some, or all?
    Int J Radiat Oncol Biol Phys. 2021;111:965-967.
    PubMed    
    
    
    
70. ROY S, Spratt DE, Morgan SC, Zhou M, et al
    Association of Short-term Patient-reported Outcomes with Long-term Oncologic Outcomes in Localized Prostate Cancer Patients Treated with Radiotherapy and ADT in a Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2021 Nov 14. pii: S0360-3016(21)03118.
    PubMed     Abstract available
    
    
    
71. HANNAN R, Salamekh S, Desai NB, Garant A, et al
    Stereotactic Ablative Radiotherapy for High-Risk Prostate Cancer-a Prospective Multi-level MRI-based Dose Escalation Trial.
    Int J Radiat Oncol Biol Phys. 2021 Nov 10. pii: S0360-3016(21)03047.
    PubMed     Abstract available
    
    
    
72. SINZABAKIRA F, Heemsbergen WD, Pos F, Incrocci L, et al
    Patient-reported outcomes in the acute phase of the randomized hypofractionated irradiation for prostate cancer (HYPRO) trial.
    Int J Radiat Oncol Biol Phys. 2021 Nov 2. pii: S0360-3016(21)03049.
    PubMed     Abstract available
    
    
    
73. ENNIS RD, Vapiwala N
    The Fallacy of the Consultation and Informed Consent Process in Radiation Oncology Through the Lens of Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111:643-646.
    PubMed    
    
    
    
74. JASSAR H, Tai A, Chen X, Keiper T, et al
    Real-Time Motion Tracking Based on Orthogonal Cine MRI During MR-Guided Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
75. CHEN GP, Tai A, Omari EA, Bedi M, et al
    Real-Time Motion Tracking and Correction During Tomotherapy for Prostate Cancer: Impact of Fiducial Migration.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
76. BRENNEMAN RJ, Andruska N, Roy A, Waters MR, et al
    Characterization of a Novel Radiopaque Perirectal Hydrogel Spacer for Prostate Cancer Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
77. WU TC, Xiang M, Nickols NG, Tenn SE, et al
    Prostate-Centric vs. Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer With Simultaneous Integrated Boost: A Dosimetric Comparison.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
78. TAKAGI M, Hasegawa Y, Tateoka K, Takada Y, et al
    Dosimetric Study of Proton Therapy Using Scanning Method for Localized Prostate Cancer Patients in Comparison With Wobbler Method and Volumetric-Modulated Arc Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
79. GALLITTO M, Mayeda M, Hwang ME, Rayn K, et al
    Factors Contributing to Bladder Filling Variability in Patients Receiving Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
80. SONG Y, Ko WC, Tamas P, Hsu HY, et al
    Effects of Bladder Filling and Rectal Gas on Number of CBCT Scans and Treatment Time for Prostate Cancer Patients Undergoing EBRT.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
81. CARRASQUILLA M, O'Connor T, Zwart A, Danner M, et al
    Safety and Early Efficacy of Involved Field SBRT for Nodal Oligo-Recurrent Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
82. POWELL A, Goldstein JP, Lucas ER, Long J, et al
    The Association Between Use of Hypofractionated Radiation Therapy for the Treatment of Prostate Cancer and Treatment Completion.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
83. BATES JE, Sanders T, Arnone A, Elmore SNC, et al
    Geographic Density of Linear Accelerators and Receipt of Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
84. KOWALCHUK RO, Breen W, Harmsen WS, Jeans E, et al
    Cost-Effectiveness of Treatment Strategies for High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
85. DEE EC, Taunk NK, Deville C Jr, Mahal BA, et al
    Trends in Receipt of Shorter Regimens of Radiation Therapy and Treatment Noncompletion Disparities Among Breast and Prostate Cancer Patients in the United States.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
86. JOOYA A, Qureshi D, Leigh J, Webber C, et al
    Barriers to Access Palliative Radiotherapy in Prostate Cancer - A Population-Based Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
87. MEEM M
    Dose-Escalated External-Beam Radiation to Prostate and Pelvic Nodes in High-Risk Prostate Cancer: Long-Term Toxicities and Outcomes at a Tertiary Center.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
88. KRUGER J, Bylund KC, Cummings MA, Frye T, et al
    Role of Pelvic Radiation in Management of Non-Metastatic Pathological Node-Positive Prostate Cancer: A Single Institution Experience.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
89. ZAPATERO A, Castro P, Roch M, Buchser D, et al
    VMAT Focal Boost to MRI-Defined Intraprostatic Lesion in Localized Prostate Cancer: Results of a Phase II Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
90. YOON JJ, Sayan M, Wang SJ, Watts A, et al
    Effect of Hydrogel Rectal Spacer on Intrafraction Prostate Motion During Radiotherapy of Prostate Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
91. WILLEN B, Krauss DJ, Nandalur SR, Ye H, et al
    High Dose Rate Brachytherapy as Monotherapy vs. External Beam With HDR Boost in Unfavorable Intermediate Risk Localized Prostate Cancer: A Matched-Pair Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
92. WEG ES, Holt SK, Elia M, Schade G, et al
    Assessing the Risk of Pathologic Lymph Node Involvement in Intermediate Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
93. TRAN PT, Berlin A, Siva S, Reynders D, et al
    Individual Patient Level Meta-Analysis of Prospective Trials Studying Metastasis-Directed Therapy for Metachronous Oligometastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
94. SUTERA P, Van der Eecken K, Kishan AU, Hamid A, et al
    Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
95. SMITH CP, Xiang M, Armstrong WR, Nickols NG, et al
    Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post-Hoc Analysis of Two Prospective Ga-68-PSMA PET/CT Imaging Trials.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
96. SHULMAN RM, Wong JK, Handorf E, Salama JK, et al
    Dosimetric Predictors of Toxicity in Patients With Early-Stage Prostate Cancer Treated With Moderately Hypofractionated IMRT or PBT: A Multi-Institutional Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
97. SHABSOVICH D, Xiang M, Katz AW, Mantz CA, et al
    Patterns and Predictors of Distant Failure After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Retrospective Multi-Institutional Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
98. SANDOVAL ML, Latifi K, Parsee A, Andreozzi J, et al
    Defining MR-Based Parameters of Treatment Response to Immune-Modulatory Therapy for Grade Group 5 Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
99. QI X, Gao XS
    Radiotherapy of the Primary Tumor and All Metastatic Lesions in Synchronous Oligometastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available
    
    
    
100. PAPANIKOLAOU P, Swanson GP, Stathakis S, Fakhreddine M, et al
     Estimation of Dose-Response Correlations Regarding Significant Blood Count Drops After Radiotherapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
101. ONAL C, Kose F, Ozyigit G, Aksoy S, et al
     Stereotactic Body Radiotherapy for Oligoprogressive Lesions in Metastatic Castration-Resistant Prostate Cancer Patients During Abiraterone/Enzalutamide Treatment.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
102. ONAL C, Ozyigit G, Oymak E, Guler OC, et al
     Stereotactic Radiotherapy to Oligoprogressive Lesions Detected With (68)Ga-PSMA-PET/CT in Castration-Resistant Prostate Cancer Patients.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
103. OLSON AC, Skiba JH, Gill BS, Wang H, et al
     A Prospective, Single-Arm, Phase II, Multi-Center Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
104. NIHEI K, Nakamura K, Karasawa K, Saito Y, et al
     A Japanese Multi-Institutional Phase II Study of Moderate Hypofractionated Intensity-Modulated Radiotherapy With Image-Guided Technique for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
105. NAVARRO I, Joseph L, Liu Z, Berlin A, et al
     Physician and Patient Reported Morbidity After MR-Guided Salvage Brachytherapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
106. MONINGI S, Johnson HK, Peng LC, Leeman JE, et al
     Could an Academic Review of Pathology Lead to Changes in Patient Care in Men With Prostate Cancer?
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
107. MISZCZYK M, Jablonska I, Krzysztofiak T, Magrowski L, et al
     Does Brachytherapy Boost Improve Biochemical Control in Intermediate and High-Risk Prostate Cancer Patients Compared to External Beam Radiotherapy Alone?
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
108. MCDONALD AM, DeMora L, Lenzie A, Hoyle J, et al
     Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
109. MA W, Tao W, Hara D, Shi J, et al
     The Dual Effect of the HDAC Inhibitor Romidepsin on Androgen Receptor Signaling and DNA Damage Repair in Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
110. MA TM, Roy S, Mantz CA, Fuller DB, et al
     Working Towards a New Definition of Biochemical Failure in the Era of Stereotactic Body Radiation Therapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
111. LIN EY, Lee A, Demanes J, Kamrava M, et al
     High-Dose Rate (HDR) Brachytherapy is a Safe and Effective Treatment for Prostate Cancer Patients With Prior Transurethral Resection of the Prostate (TURP).
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
112. KOONTZ BF, Hoffman KE, Oyekunle T, George DJ, et al
     Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
113. KERNS SL, Morlang A, Lee SM, Hall WA, et al
     Use of Angiotensin Converting Enzyme Inhibitors and Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
114. KAMRAN SC, Aldrighetti C, Oladeru OT, Niemierko A, et al
     Impact of the COVID-19 Pandemic on Prostate Cancer Radiotherapy Practice Patterns: A Northeast Regional Longitudinal Survey Study.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
115. JENSEN GL, Hammonds K, Jhavar SG, Swanson GP, et al
     Functional Outcomes With Dose-Escalated, Conventionally Dosed, or Without Nodal Irradiation in Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
116. JAWORSKI E, Fang F, Gharzai LA, McFarlane M, et al
     Utility of Long-Term Follow-Up to Determine Safety in Radiotherapy-Specific Trials for Localized Prostate Cancer: Meta-Analysis of 29 Randomized Trials.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
117. HUTTEN R, Parsons MW, Khouri A, Tward A, et al
     The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
118. HASKINS C, Siddiqui OM, Lin JY, Bentzen SM, et al
     Rectal Volume and Quality of Life in Prostate Cancer Patients Receiving Pediococcus-Based Probiotics and Radiation Therapy: A Prospective Randomized Trial.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
119. HAAS JA, Mendez C, Katz A, Witten MR, et al
     Robotic SBRT in Prostate Cancer Patients Younger Than 50 Years Old.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
120. GOROVETS D, Tin A, Vickers AJ, Zelefsky MJ, et al
     Patient-Reported Financial Toxicity Following Definitive Radiation Therapy for Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
121. GLICKSMAN R, Kishan AU, Katz AJ, Mantz CA, et al
     4-Year PSA Response Rate as a Predictive Measure in Intermediate Risk Prostate Cancer Treated With Ablative Therapies: The Sprat Analysis.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
122. LALLA VD, Elakshar S, Anidjar M, Bahoric B, et al
     Salvage External Beam Radiotherapy After HIFU Failure in Localized Prostate Cancer: A Single Institution Experience.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
123. DHERE VR, Fischer-Valuck BW, Goyal S, Liu Y, et al
     Toxicity Outcomes After Low-Dose-Rate vs. High-Dose-Rate Brachytherapy Boost in Combination With External Beam Radiation for Intermediate and High-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
124. DHERE VR, Schuster DM, Goyal S, Schreibmann E, et al
     Randomized Trial of Conventional vs Conventional Plus Fluciclovine ((18)F) PET/CT-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer: Volumetric and Patient-Reported Toxicity Analyses.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
125. DELGADILLO R, Spieler B, Deana A, Ford J, et al
     Cone Beam CT Based Delta-Radiomics of Prostate Cancer Patients and Their Correlation to Quality of Life, Genitourinary and Gastrointestinal Toxicities.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
126. DEE EC, Muralidhar V, King MT, Martin NE, et al
     Association Between Treatment Modality and Probability of Second Malignancy in Localized Prostate Cancer Patients.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
127. CORKUM MT, Morton G, Loblaw DA, Tseng CL, et al
     A Prospective Study of MR-Guided Focal Salvage High Dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
128. CHIRILA ME, Brausi M, Chatterjee P, Gordon K, et al
     Salvage Treatments for the Local Recurrence of Prostate Cancer After Radiotherapy - Results of an International Multidisciplinary Survey.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
129. CHEUNG P, Tseng CL, Chung HR, Chu W, et al
     Intermittent Androgen Deprivation Therapy Plus Comprehensive Stereotactic Radiotherapy for Oligometastatic Prostate Cancer (CROP).
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
130. CHAPMAN D, Quinn TJ, Hamstra DA
     Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiotherapy.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
131. BRYANT CM, Henderson RH, Mendenhall WM, Nichols RC Jr, et al
     10-Year Outcomes Following Proton Therapy for Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
132. BHANGOO RS, DeWees TA, Thorpe CS, Petersen M, et al
     Updated Toxicity and Quality-of-Life Outcomes From a Randomized Phase III Trial of Extreme Hypofractionated vs. Standard Fractionated Proton Therapy for Low-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
133. BERGHEN C, Joniau S, Rans K, Poels K, et al
     Metastasis-Directed Therapy for Oligoprogressive Castration-Resistant Prostate Cancer - Preliminary Results of the Prospective, Single-Arm MEDCARE Trial.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
134. AZGHADI S, Abdelhafez Y, Parikh M, Stephen M, et al
     Detectability Rates and Impact on Management From High-Sensitivity Total-Body (18)F-Fluciclovine PET/CT Scans in Patients With Prostate Cancer Biochemical Recurrence.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
135. ANDRUSKA N, Diaz EJ, Gay HA, Agabalogun T, et al
     Can EBRT Dose-Escalation Above 80 Gy Yield Comparable Survival Rates Relative to EBRT Plus Brachytherapy Boost in Men With Unfavorable Intermediate-Risk Prostate Cancer?
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
136. AGABALOGUN T, Andruska N, Fischer-Valuck BW, Gay HA, et al
     Comparative Effectiveness of the Brachytherapy Boost and Androgen Deprivation Therapy for African-American Men with Unfavorable Intermediate-Risk Prostate Cancer Treated With External Beam Radiotherapy.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
137. CHEBRA I
     Apoptosis and Senescence in Localized Prostate Cancer Tissues Treated With HDR-BT Boost With Radiotherapy (EBRT) and ADT.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
138. HARA D, Shi J, Tao W, Ma W, et al
     Impact of PSMA Targeted Gold Nanoparticles on Prostate Cancer Radiation Bystander Effect.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
139. RAJKUMAR AW, Wang J, Chennupati DV, Kirschner AN, et al
     Optimizing STING Activity in Prostate Cancer Pre-Clinical Models.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
140. FAIELLA A, Palermo B, Bottero M, Panetta M, et al
     Immunomonitoring During Radiotherapy of Prostate Cancer: Effect of Dose & Volume on Peripheral Immune Cells.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
141. CHEBRA I
     Effects of Androgen Deprivation Therapy (ADT) Combined With Radiotherapy (EBRT) and HDR-BT Boost on DNA Repair Markers in Prostate Carcinoma.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
142. CANTALINO JM, Singh T, Zwart A, Danner M, et al
     Ejaculatory Function Following Stereotactic Body Radiation Therapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
143. GEWANTER RM, Gross J, Mazzarella K, Urban J, et al
     Does the I-PSS Accurately Assess Urinary Function in Prostate Cancer Patients? Evidence From a Study of Nursing Verification of Patient Answers.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
144. CRUICKSHANK I, Deville C Jr, Chen H, Halthore AN, et al
     Comparative In Silico Analysis of Intensity Modulated Scanning Beam Proton Therapy (IMPT) and Volumetric Modulated Arc Photon Radiotherapy (VMAT) for the Post-Operative Treatment of Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
145. ZHU S, Elshaikh MA, Movsas B, Wen N, et al
     Automatic Prediction of 3D Radiation Dose Distribution in Prostate Cancer Treated with Volumetric Modulated Arc Therapy (VMAT) Using a Conditional Generative Adversarial Network (cGAN).
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
146. SURESH R, Niemela J, Akram S, Valdman A, et al
     A Comparative Study Between AI-Generated, Real-Life Clinical as Well as Reference Rectal Volumes Defined in Accordance With the Swedish National STRONG Guidelines in Prostate Cancer Radiotherapy.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
147. DUAN J, Bernard ME, Downes L, Clair WS, et al
     A Double-Blind Study to Evaluate the Feasibility of Using AI-Powered Auto-Segmentation in Prostate Cancer Treatment.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
148. BOYD GH, Efstathiou JA, Kamran SC, Zietman AL, et al
     Qualitative and Quantitative Analysis of a Deep Learning Auto Contouring Model for Radiotherapy in Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
149. MURAKAMI Y, Soyano T, Kozuka T, Ushijima M, et al
     Can Dosiomics Features Be Relevant Predictive Factors for Biochemical Recurrence After Radiotherapy in Prostate Cancer Patients?
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
150. YANG F, Ghosh S, Yee D, Patel SI, et al
     Conventional vs. Hypofractionation Radiation for High-Risk Prostate Cancer Patients (CHIRP): 24 Months Patient-Reported Quality of Life Outcomes of the Randomized Phase II CHIRP Trial.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
151. DESS RT, Sun Y, Bolla M, Zapatero A, et al
     Prognostic and Predictive Performance of Routine Clinicopathologic Variables in 10,535 Men Enrolled on Randomized Phase III Trials in Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
152. KISHAN AU, Romero T, Wang X, Pisansky TM, et al
     Impact of High DosE rAdioTherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
153. KWOK Y, Mirkheshti N, Naslund M, Hussain A, et al
     A Prospective Trial of Aggressive Therapy Consisting of Neoadjuvant Chemotherapy and Androgen Deprivation Followed by Prostatectomy and Adjuvant Radiation in High/Very High-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
154. ZAPATERO A, Grande ADG, Maldonado X Sr, Alvarez A, et al
     10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
155. KISHAN AU, Wong JK, Merrick GS, Tran PT, et al
     The Relationship Between Androgen Deprivation Therapy Duration and External Beam Radiotherapy With or Without a Brachytherapy Boost in High-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
156. MALONE S, Spratt DE, Morgan SC, Grimes S, et al
     Association of Short-Term Patient-Reported Outcomes With Long-Term Oncologic Outcomes in Localized Prostate Cancer Treated With Radiotherapy and ADT in a Phase III Randomized Controlled Trial.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
157. ROY S, Morgan SC, Spratt DE, Grimes S, et al
     Association of Baseline Health-Related Quality of Life Metrics With Outcome in Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
158. DE B, Pasalic D, Barocas DA, Zhao Z, et al
     Five-Year Outcomes From a Prospective Comparative Effectiveness Study Evaluating External Beam Radiotherapy With Low Dose-Rate Brachytherapy Boost and Prostatectomy for Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
159. KATZ A, Cao Y, Shen X, Usinger DS, et al
     Associations Between Knowledge of Others' Experiences and Patient Perceptions of Treatments for Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
160. BOYAJIAN R, Gordon WJ, Kowtoniuk AM, Boyajian KR, et al
     Development & Impact of a Virtual PSA Monitoring Clinic for Follow-up of Prostate Cancer Patients: An Efficient Model With Unique Benefits Relevant to COVID-19.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
161. CONDE-MORENO AJ, Lopez F, Hervas A, Morillo V, et al
     Phase II Trial of SBRT and Androgen Deprivation for Oligometastases in Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
162. GAUDREAULT M, Chang D, Hardcastle N, Jackson P, et al
     Evaluation of PSMA-PET Biology-Guided Radiotherapy Sequential Boost to the PSMA-avid Subvolume in the Prostate Region in Low-Volume Advanced Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
163. MA TM, Xiang M, Tilki D, Karnes RJ, et al
     Prognostic Significance of the Risk of Non-localized Disease on PSMA/PET: Comparative Performance of a Novel, PSMA/PET-Derived Risk Stratification Tool for High-Risk Prostate Cancer in a Large, Multi-Institutional Cohort.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
164. HAMMER L, Jiang R, Hearn JWD, Dess RT, et al
     A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) Prior to Radical Prostatectomy (RP) in Locally Advanced Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
165. NGUYEN PL, Huang HC, Davicioni E, Sandler HM, et al
     Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
166. KISHAN AU, Sun Y, Pisansky TM, Bolla M, et al
     Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
167. DAI Z, Jambor I, Taimen P, Pantelic M, et al
     Accurate Prostate Cancer Detection and Segmentation Using Non-Local Mask R-CNN With Histopathological Ground Truth.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
168. KANWAR A, Claunch C, Rana S, Merz B, et al
     Evaluation of Commercial Pelvic Autosegmentation Solutions in Anatomic Edge Cases of Patients Receiving Definitive Radiotherapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
169. MOVSAS B, Rodgers J, Elshaikh MA, Martinez AA, et al
     Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
170. SPIELER B, Khodor Y, Chakrabortty S, Fischer C, et al
     Plasma Exosomal RNA Biomarkers of High-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
171. GLICKSMAN R, Liu SK, Cheung P, Vesprini D, et al
     Elective Nodal Ultra Hypofractionated Radiation for Prostate Cancer: Safety and Efficacy From Four Prospective Clinical Trials.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
172. PADAYACHEE J, Sanmamed N, Lee J, Liu Z, et al
     Local Control in Tumor-Targeted Dose Escalation for Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
173. YAMOAH K, Lee KM, Alba PR, Awasthi S, et al
     Defining Racial Disparities Across the Prostate Cancer Disease Continuum in an Equal Access-to-Care Setting Within the Nation's Largest Healthcare Network.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
174. GLICKSMAN R, Loblaw DA, Morton G, Szumacher E, et al
     Elective Pelvic Nodal Irradiation With A Simultaneous Hypofractionated Integrated Prostate Boost for Localized High Risk Prostate Cancer: Long Term Results From a Prospective Clinical Trial.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
175. SALERNO KE, Turkbey B, Lindenberg L, Mena E, et al
     Detection of Failure Patterns Using Advanced Imaging in Patients With Biochemical Recurrence Following Low Dose Rate Brachytherapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     
176. KRAUSS DJ, Karrison TG, Martinez AA, Morton G, et al
     Dose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized Trial.
     Int J Radiat Oncol Biol Phys. 2021;111.
     PubMed     Abstract available
     
     
     October 2021
177. MUSUNURU HB, Cheung P, Vesprini D, Liu SK, et al
     Gantry-based 5-fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes from 2 Prospective Studies comparing SABR Boost with MR Dose Painted HDR Brachytherapy Boost.
     Int J Radiat Oncol Biol Phys. 2021 Oct 9. pii: S0360-3016(21)02899.
     PubMed     Abstract available
     
     
     September 2021
178. JONES CU, Pugh SL, Sandler HM, Chetner MP, et al
     Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial.
     Int J Radiat Oncol Biol Phys. 2021 Sep 1. pii: S0360-3016(21)02724.
     PubMed     Abstract available
     
     
     
179. NAGAR H, Spratt DE
     Prostate SBRT Dose Escalation (9 Gyx5, 13.3 Gyx3, 24 Gyx1): Are We Making Progress?
     Int J Radiat Oncol Biol Phys. 2021;111:110-112.
     PubMed    
     
     
     August 2021
180. NUIJENS AC, Oei AL, van Oorschot B, Visser J, et al
     Gamma-H2AX Foci Decay Ratio as a Stronger Predictive Factor of Late Radiation Toxicity than Dose-Volume Parameters in a Prospective Cohort of Prostate Cancer Patients.
     Int J Radiat Oncol Biol Phys. 2021 Aug 19. pii: S0360-3016(21)02708.
     PubMed     Abstract available
     
     
     
181. MURAKAMI Y, Soyano T, Kozuka T, Ushijima M, et al
     Dose-based radiomic analysis (dosiomics) for intensity-modulated radiotherapy in patients with prostate cancer: Correlation between planned dose distribution and biochemical failure.
     Int J Radiat Oncol Biol Phys. 2021 Aug 5. pii: S0360-3016(21)02627.
     PubMed     Abstract available
     
     
     
182. FERREIRA MR, Sands CJ, Li JV, Andreyev JN, et al
     Impact of pelvic radiotherapy for prostate cancer on global metabolic profiles and microbiota-driven gastrointestinal late side-effects: a longitudinal observational study.
     Int J Radiat Oncol Biol Phys. 2021 Aug 2. pii: S0360-3016(21)02626.
     PubMed     Abstract available
     
     
     
183. LEITE ETT, Ramos CCA, Moraes FY
     In Reply to Fiorino et al.
     Int J Radiat Oncol Biol Phys. 2021;110:1549-1550.
     PubMed    
     
     
     
184. ARAI TJ, Yang DM, Campbell JW 3rd, Chiu T, et al
     Oxygen-Sensitive MRI: A Predictive Imaging Biomarker for Tumor Radiation Response?
     Int J Radiat Oncol Biol Phys. 2021;110:1519-1529.
     PubMed     Abstract available
     
     
     
185. PRASANNA PG, Rawojc K, Guha C, Buchsbaum JC, et al
     Normal Tissue Injury Induced by Photon and Proton Therapies: Gaps and Opportunities.
     Int J Radiat Oncol Biol Phys. 2021;110:1325-1340.
     PubMed     Abstract available
     
     
     July 2021
186. PARZEN JS, Hamstra DA
     Patient-Reported Quality of Life During Prostate Cancer Radiation Therapy: Insights Into the Patient Experience.
     Int J Radiat Oncol Biol Phys. 2021;110:1129-1131.
     PubMed    
     
     
     
187. CHOUDHURY A, Henry Md Frcr A, Mitin Md PhD T, Chen Md Mph R, et al
     Photons, Protons, SBRT, Brachytherapy-What Is Leading the Charge for the Management of Prostate Cancer? A Perspective From the GU Editorial Team.
     Int J Radiat Oncol Biol Phys. 2021;110:1114-1121.
     PubMed    
     
     
     
188. EFSTATHIOU JA, Kamran SC, Spratt DE
     Protons Versus Photons for Prostate Cancer: An Answer That Is Long Overdue and Coming.
     Int J Radiat Oncol Biol Phys. 2021;110:1098-1100.
     PubMed    
     
     
     
189. PARKER C
     Timing of Postoperative Radiation Therapy After Radical Prostatectomy.
     Int J Radiat Oncol Biol Phys. 2021;110:1132-1134.
     PubMed    
     
     
     
190. YANG Y, Vargas CE, Bhangoo RS, Wong WW, et al
     Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity Modulated Proton Therapy (IMPT).
     Int J Radiat Oncol Biol Phys. 2021;110:1189-1199.
     PubMed     Abstract available
     
     
     
191. SCHUMACHER O, Luo H, Taaffe DR, Galvao DA, et al
     Effects of exercise during radiotherapy on physical function and treatment-related side effects in men with prostate cancer: a systematic review and meta-analysis.
     Int J Radiat Oncol Biol Phys. 2021 Jul 8. pii: S0360-3016(21)00841.
     PubMed     Abstract available
     
     
     
192. BERTHOLD J, Khamfongkhruea C, Petzoldt J, Thiele J, et al
     First-in-human validation of CT-based proton range prediction using prompt gamma imaging in prostate-cancer treatments.
     Int J Radiat Oncol Biol Phys. 2021 Jul 3. pii: S0360-3016(21)00843.
     PubMed     Abstract available
     
     
     
193. KISHAN AU, Collins SP
     Quality of Life After Prostate Cancer Treatment.
     Int J Radiat Oncol Biol Phys. 2021;110:727-730.
     PubMed    
     
     
     
194. MOHAMAD O, Feng F
     Treating Localized High-Risk Prostate Cancer: Do All Roads Lead to Rome?
     Int J Radiat Oncol Biol Phys. 2021;110:634-635.
     PubMed    
     
     
     
195. BELKACEMI Y, Coraggio G, Loganadane G
     Management Strategy of High-Risk Localized Prostate Cancer: Is there a Transatlantic Consensus?
     Int J Radiat Oncol Biol Phys. 2021;110:631-632.
     PubMed    
     
     
     
196. RANS K, De Meerleer G, Joniau S, Baten A, et al
     In Regard to Zelefsky et al.
     Int J Radiat Oncol Biol Phys. 2021;110:910-911.
     PubMed    
     
     
     
197. WALSHAW RC, Hoskin PJ, Choudhury A
     Can Hypofractionation and Immune Modulation Coexist?
     Int J Radiat Oncol Biol Phys. 2021;110:742-744.
     PubMed    
     
     
     
198. WALLIS CJD, Klotz L, Satkunasivam R, Klaassen Z, et al
     Not So "Active" Surveillance.
     Int J Radiat Oncol Biol Phys. 2021;110:716-717.
     PubMed    
     
     
     
199. SHORTALL J, Palma G, Mistry H, Vasquez Osorio E, et al
     Flogging a Dead Salmon? Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
     Int J Radiat Oncol Biol Phys. 2021;110:696-699.
     PubMed    
     
     
     
200. CHEN RC
     A Trans-Atlantic Voyage of Extended ADT With Local Radiation.
     Int J Radiat Oncol Biol Phys. 2021;110:633.
     PubMed    
     
     
     
201. VAN DAMS R, Jiang NY, Fuller DB, Loblaw A, et al
     Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.
     Int J Radiat Oncol Biol Phys. 2021;110:731-737.
     PubMed     Abstract available
     
     
     
202. HSU IC, Rodgers JP, Shinohara K, Purdy J, et al
     Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.
     Int J Radiat Oncol Biol Phys. 2021;110:700-707.
     PubMed     Abstract available
     
     
     June 2021
203. BRAND DH, Bruningk SC, Wilkins A, Fernandez K, et al
     Estimates of Alpha/Beta (alpha/beta) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
     Int J Radiat Oncol Biol Phys. 2021;110:596-608.
     PubMed     Abstract available
     
     
     May 2021
204. NITHIYANANTHAN K, Creighton N, Currow D, Martin JM, et al
     Population-Level Uptake of Moderately Hypofractionated Definitive Radiotherapy in the Treatment of Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2021 May 8. pii: S0360-3016(21)00460.
     PubMed     Abstract available
     
     
     
205. HARA D, Tao W, Totiger T, Pourmand A, et al
     Prostate Cancer Targeted X-ray Fluorescence Imaging via Gold Nanoparticles Functionalized with Prostate-Specific Membrane Antigen (PSMA).
     Int J Radiat Oncol Biol Phys. 2021 May 5. pii: S0360-3016(21)00459.
     PubMed     Abstract available
     
     
     
206. WANG K, Mavroidis P, Royce TJ, Falchook AD, et al
     Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response.
     Int J Radiat Oncol Biol Phys. 2021;110:237-248.
     PubMed     Abstract available
     
     
     April 2021
207. NABID A, Carrier N, Vigneault E, Van Nguyen T, et al
     OPTIMIZING TREATMENT IN INTERMEDIATE RISK PROSTATE CANCER: SECONDARY ANALYSIS OF A RANDOMIZED PHASE III TRIAL.
     Int J Radiat Oncol Biol Phys. 2021 Apr 23. pii: S0360-3016(21)00373.
     PubMed     Abstract available
     
     
     
208. MASTERS SC, Hofling AA, Gorovets A, Marzella L, et al
     FDA Approves Ga 68 PSMA-11 for Prostate Cancer Imaging.
     Int J Radiat Oncol Biol Phys. 2021 Apr 12. pii: S0360-3016(21)00357.
     PubMed    
     
     
     
209. LEITE ETT, Ramos CCA, Ribeiro VAB, Salvajoli BP, et al
     Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
     Int J Radiat Oncol Biol Phys. 2021;109:1263-1270.
     PubMed     Abstract available
     
     
     
210. FU SY, Chen FH, Wang CC, Yu CF, et al
     Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment.
     Int J Radiat Oncol Biol Phys. 2021;109:1547-1558.
     PubMed     Abstract available
     
     
     
211. ROBIN S, Jolicoeur M, Palumbo S, Zilli T, et al
     Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2021;109:1243-1253.
     PubMed     Abstract available
     
     
     March 2021
212. BUSZEK SM, Ludmir EB, Grosshans DR, McAleer MF, et al
     Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
     Int J Radiat Oncol Biol Phys. 2021;109:718-725.
     PubMed     Abstract available
     
     
     
213. SHAHI J, Poon I, Ung YC, Tsao M, et al
     Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
     Int J Radiat Oncol Biol Phys. 2021;109:764-774.
     PubMed     Abstract available
     
     
     December 2020
214. MARCELLO M, Denham JW, Kennedy A, Haworth A, et al
     Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
     Int J Radiat Oncol Biol Phys. 2020;108:1304-1318.
     PubMed     Abstract available
     
     
     November 2020
215. BOHMER D, Hocht S, Wiegel T
     Moving Beyond the Hazard Ratio to Personalized Therapy: Is it Prime Time?
     Int J Radiat Oncol Biol Phys. 2020;108:903-904.
     PubMed    
     
     
     
216. SHI J, Xu K, Keyvanloo A, Udayakumar TS, et al
     A Multimodality Image Guided Precision Radiation Research Platform: Integrating X-ray, Bioluminescence, and Fluorescence Tomography With Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2020;108:1063-1072.
     PubMed     Abstract available
     
     
     
217. TABRIZI S, Alshalalfa M, Mahal BA, Davicioni E, et al
     Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.
     Int J Radiat Oncol Biol Phys. 2020;108:936-940.
     PubMed     Abstract available
     
     
     
218. VOGELIUS IR, Bentzen SM
     In Reply to Berk and Alfonso.
     Int J Radiat Oncol Biol Phys. 2020;108:834-835.
     PubMed    
     
     
     
219. GUTIONTOV SI, Pitroda SP, Weichselbaum RR
     Oligometastasis: Past, Present, Future.
     Int J Radiat Oncol Biol Phys. 2020;108:530-538.
     PubMed     Abstract available
     
     
     
220. MAO X, Pineau J, Keyes R, Enger SA, et al
     RapidBrachyDL: Rapid Radiation Dose Calculations in Brachytherapy Via Deep Learning.
     Int J Radiat Oncol Biol Phys. 2020;108:802-812.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: